about
Coadjuvants in the Diabetic Complications: Nutraceuticals and Drugs with Pleiotropic EffectsMechanism of resveratrol-induced relaxation in the human gallbladder.High Glucose Level Disturbs the Resveratrol-Evoked Curtailment of CX3CL1/CX3CR1 Signaling in Human Placental CirculationN-acetylcysteine attenuates myocardial dysfunction and postischemic injury by restoring caveolin-3/eNOS signaling in diabetic rats.Targeting extracellular matrix remodeling in disease: Could resveratrol be a potential candidate?Adenosine Monophosphate (AMP)-Activated Protein Kinase: A New Target for Nutraceutical CompoundsMechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor.Resveratrol and polydatin as modulators of Ca(2+) mobilization in the cardiovascular system.SIRT1 Activation by Resveratrol Alleviates Cardiac Dysfunction via Mitochondrial Regulation in Diabetic Cardiomyopathy Mice.Efficacy of resveratrol to supplement oral nifedipine treatment in pregnancy-induced preeclampsiaA Comparative Study of Phenols in Apulian Italian Wines.Cardioprotective effect of Notch signaling on the development of myocardial infarction complicated by diabetes mellitusDosis Facit Sanitatem-Concentration-Dependent Effects of Resveratrol on Mitochondria.SIRT1 Regulates Cognitive Performance and Ability of Learning and Memory in Diabetic and Nondiabetic Models.Epigenetic Regulatory Mechanisms Induced by Resveratrol.Red Wine, Resveratrol and Atrial Fibrillation.Dietary Polyphenols in the Prevention of Stroke.Maternal Resveratrol Treatment Reduces the Risk of Mammary Carcinogenesis in Female Offspring Prenatally Exposure to 2,3,7,8-Tetrachlorodibenzo-p-Dioxin.Tocotrienol is a cardioprotective agent against ageing-associated cardiovascular disease and its associated morbidities.Dietary resveratrol improves antioxidant status of sows and piglets and regulates antioxidant gene expression in placenta by Keap1-Nrf2 pathway and Sirt1.Therapeutic Potential of Polyphenols in Cardiac Fibrosis.An overview on the interplay between nutraceuticals and gut microbiota.Aryl Hydrocarbon Receptor: A New Player of Pathogenesis and Therapy in Cardiovascular Diseases.Anti-Inflammatory Effects of Resveratrol: Mechanistic Insights.Developmental Programming of the Metabolic Syndrome: Can We Reprogram with Resveratrol?Maternal Resveratrol Therapy Protects Male Rat Offspring against Programmed Hypertension Induced by TCDD and Dexamethasone Exposures: Is It Relevant to Aryl Hydrocarbon Receptor?
P2860
Q26741423-FFA15947-0BE2-4D6A-BF96-A77880B857F6Q33651451-ADBDEE02-1AF2-43E3-84EC-BB422423FF52Q33800749-2B6F86EB-0908-4C50-8D0A-C448955B04C9Q37336736-B8989EB0-5E77-4A7A-AD82-410CF7D62E1BQ38995157-C080F475-61A5-452A-B12A-7AFBBF37306DQ39113371-477C12DB-3BA6-437E-9AA5-C7DEDCD5BF9AQ39176010-F1C81D8A-84D6-43FB-8953-9BC8D05A4536Q39406728-D72770AB-896F-476B-A5A8-1A3C672ECCBAQ41528591-626CD1FA-4765-4007-B362-29254C813385Q42269581-C8B3AFF8-A932-4CA9-A424-BD6129822C05Q42290193-8206815E-F2F7-46E0-A4D7-9AA0C663F678Q42376410-7CF42F90-FEFD-47F6-8726-53E966F2C910Q44323696-1AFA65CE-93A9-4AAC-830A-8C64A1649390Q46772238-D2F68B1C-FB59-4F97-9D96-3D0702621C3AQ47115527-80B45E0E-6E4E-4A67-8361-48310FCD4895Q47118426-D6C18CE3-7BC7-4F2F-BE5D-7A895CC7B469Q47163649-B5CDA0A3-85AA-488C-9AAF-4873497012A1Q47673719-3F70C4D0-6962-47C6-9D9D-B5DFE60B60ADQ48129928-87FA5214-668B-48E5-A938-C67E3BD734A3Q54974296-55AD68BB-FEC9-4A12-BE08-1D95230CBE62Q55289622-D05D3B50-4249-4DC3-8F86-A83ECF6D4902Q55307054-7D2F43FB-9311-463A-8474-CB61DE4A4851Q55500224-11823D3D-F4C5-41C6-A754-412408DDF439Q55560479-79BFFE06-D53D-45F0-8642-8EA75F0B9028Q57844786-02B72FEA-E770-4003-8D21-1D0C7CA771A0Q57844797-BF5A6961-B043-4CD1-8E67-D89698A1C756
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Resveratrol and Cardiovascular Diseases
@ast
Resveratrol and Cardiovascular Diseases
@en
Resveratrol and Cardiovascular Diseases
@nl
type
label
Resveratrol and Cardiovascular Diseases
@ast
Resveratrol and Cardiovascular Diseases
@en
Resveratrol and Cardiovascular Diseases
@nl
prefLabel
Resveratrol and Cardiovascular Diseases
@ast
Resveratrol and Cardiovascular Diseases
@en
Resveratrol and Cardiovascular Diseases
@nl
P2860
P921
P3181
P356
P1433
P1476
Resveratrol and Cardiovascular Diseases
@en
P2860
P3181
P356
10.3390/NU8050250
P407
P577
2016-05-02T00:00:00Z